Proteogenix는 Primary Antibody Biosimilar - Research Grade
제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.
제품 설명
제품 번호
PTXCOV-A521D
제품 특징
| Product name | Anti-CoV-RBD (A2) antibody |
|---|---|
| Species | Human |
| Expression system | Mammalian |
| Molecular weight | 150kDa |
| Purity | 85% |
| Buffer | PBS, pH7,5 |
| Form | Liquid |
| Delivery condition | Blue ice (+4°C) |
| Storage condition | 4°C for short term; -20°c or -80°C for long term |
| Brand | Proteogenix |
| Reference | PTXCOV-A521D |
| Note | For research use and in vitro diagnostic only. Not suitable for human use. |
| Isotype | IgG1 |
| Clonality | Monoclonal Antibody |
| Target | RBD domain- SARS-CoV2 Spike protein |
The anti-CoV-RBD (A2) antibody is a fully human IgG immunoglobulin designed to target the receptor-binding domain (RBD) of the new pandemic strain of coronavirus, SARS-CoV-2. Targeting this specific domain presents unique advantages when it comes to the development of COVID-19 therapeutic antibodies.
The RBD is responsible for recognizing and binding the specific cell surface marker ACE2 (angiotensin-converting enzyme 2). This interaction further leads to the proteolytic cleavage of the spike exposing the S2 subunit and initiating the formation of the membrane fusion core complex. Antibodies able to block this initial interaction are known as neutralizing antibodies (NAbs). These specific and rare antibodies are on the vanguard of COVID-19 treatments due to their ability to arrest SARS-CoV-2 infections in their earliest stages.
This new antibody was obtained by screening a high-diversity COVID-19 human antibody library (LiAb-SFCOVID-19™) using phage display technology (i.e. biopanning) and recombinantly expressed RBD as the desired target. It capitalizes on the immune repertoire developed in patients who have been infected with COVID-19. Additionally, the specificity and affinity of the newly developed molecule were tested in the ELISA platform. Its stability and ease of production were further confirmed by consistently obtaining high production yields in XtenCHO™, a transient mammalian system based on an engineered variant of CHO.
Moreover, the neutralizing activity of antibody R3P2-A2 was confirmed in vitro through the indirect detection assay: SARS-CoV-2 Surrogate Virus Neutralization kit. The assay works on the principle of direct competition between candidate antibodies and the ACE2 for the binding pocket of RBD. This antibody and other similar products serve as effective research tools to either detect the presence of SARS-CoV-2 in multiple samples in ELISA tests, as well as to potentially better understand the mechanism of infection in the new coronavirus.
QC & Validation Data
Anti-CoV-RBD (A2) antibody, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
ProteoGenix의 모든 제품들을 만나보세요!
Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"
MSDS
온라인 견적
